ACON icon

Aclarion

4.50 USD
-0.23
4.86%
At close Feb 14, 4:00 PM EST
After hours
4.43
-0.07
1.56%
1 day
-4.86%
5 days
-11.24%
1 month
-99.96%
3 months
-99.98%
6 months
-99.98%
Year to date
-99.97%
1 year
-100.00%
5 years
-100.00%
10 years
-100.00%
 

About: Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Employees: 6

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 9 [Q2] → 9 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.3% less ownership

Funds ownership: 4.01% [Q2] → 3.71% (-0.3%) [Q3]

27% less capital invested

Capital invested by funds: $94.2K [Q2] → $68.4K (-$25.8K) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$481
10,589%
upside
Avg. target
$481
10,589%
upside
High target
$481
10,589%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Ascendiant Capital
Lucas Ward
42% 1-year accuracy
5 / 12 met price target
10,589%upside
$481
Buy
Maintained
27 Nov 2024

Financial journalist opinion

Based on 6 articles about ACON published over the past 30 days

Neutral
GlobeNewsWire
6 days ago
Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body
Recent Notice of Allowance is for Aclarion's 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an intervertebral disc  Patent will expand Aclarion's proprietary rights to use MRS to measure propionic acid as a biomarker for the identification of potential infection and pain throughout the body BROOMFIELD, Colo., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its 24th issued US patent.
Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body
Neutral
GlobeNewsWire
1 week ago
Aclarion Announces Northwestern Medicine as First CLARITY Trial Site
Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan's ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc.
Aclarion Announces Northwestern Medicine as First CLARITY Trial Site
Neutral
GlobeNewsWire
1 week ago
Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded
The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trial CLARITY is a prospective, randomized, multicenter study to validate Nociscan's ability to improve surgical outcomes Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has secured full funding for its pivotal CLARITY trial which is designed to demonstrate Nociscan's clinical and economic value in spine surgery.
Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded
Neutral
MCAP MediaWire
1 week ago
Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded
Broomfield, CO, February 4, 2025 – PRISM MediaWire – Aclarion, Inc.
Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded
Neutral
MCAP MediaWire
2 weeks ago
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference
BROOMFIELD, Colo., January 31, 2025 – PRISM MediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the Selby Spine Conference.
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference
Neutral
GlobeNewsWire
2 weeks ago
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference
Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI)  NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain BROOMFIELD, Colo., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the Selby Spine Conference.
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference
Positive
Zacks Investment Research
1 month ago
Aclarion (ACON) Upgraded to Buy: Here's What You Should Know
Aclarion (ACON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aclarion (ACON) Upgraded to Buy: Here's What You Should Know
Neutral
GlobeNewsWire
2 months ago
Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash
Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients
Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash
Neutral
Accesswire
3 months ago
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
BROOMFIELD, CO / ACCESSWIRE / November 14, 2024 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq:ACON)(Nasdaq:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its participation at the upcoming Virtual Investor Summit Microcap Event on November 21st. The Company will be available for 1-on-1 meetings throughout the day in addition to its formal presentation.
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
Neutral
GlobeNewsWire
4 months ago
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Aclarion's CEO, Brent Ness, has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15th, 2024, at 2:00 p.m.
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
Charts implemented using Lightweight Charts™